tbuckley/cabot-search huggingface dataset:
TCT-35 FFR Gray zone and clinical outcome
Authors: Julien Adjedj, Bernard De Bruyne, Vincent Floré, Giuseppe Di-Gioia, Angela Ferrara, Mariano Pellicano, Gabor G. Toth, Jozef Bartunek, Marc Vanderheyden, William C. Wijns, Emanuele Barbato
Journal: Journal of the American College of Cardiology (2015)
Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Authors: Paolo Strati, Hagop M. Kantarjian, Deborah A. Thomas, Susan M. O'Brien, Elias J. Jabbour, Alfonso Quintas-Cardama, Gautam Borthakur, Stefan Faderl, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2012)
A Functional Assay for Peripheral Blood T Cells to Predict Acute Graft-Versus-Host Disease.
Authors: Carina A Baeuerlein, Christian Brede, Simone S Riedel, Ana-Laura Jordán-Garrote, Carolin Kiesel, Miriam Ritz, Stephan Schulz, Marina Grether, Georg F Beilhack, Tor B Stuge, Robert S Negrin, Hermann Einsele, Andreas Beilhack
Journal: Blood (2009)
MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study
Authors: Eric D Hsi, Lisa Rimsza, Bryan H Goldman, James R. Cook, Raymond R. Tubbs, Oliver W. Press, David G. Maloney, Richard I Fisher, John Sweetenham
Journal: Blood (2008)
Lentiviral Vector Induced Insertional Haploinsufficiency of Ebf1 Causes Leukemia in a Murine Bone Marrow Transplantation Model
Authors: Dirk Heckl, Adrian Schwarzer, Reinhard Haemmerle, Johann Meyer, Doris Steinemann, Cornelia Rudolph, Britta Skawran, Brigitte Schlegelberger, Christopher Baum, Ute Modlich
Journal: Blood (2011)
TCT-556 One-year Outcome of a Prospective Trial Stopping Dual Antiplatelet Therapy at 3-Month after Everolimus-eluting Cobalt-chromium Stent Implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
Authors: Masahiro Natsuaki, Takeshi Morimoto, Erika Yamamoto, Hiroki Shiomi, Yutaka Furukawa, Mitsuru Abe, Koichi Nakao, Tetsuya Ishikawa, Kazuya Kawai, Kei Yunoki, Shogo Shimizu, Masaharu Akao, Shinji Miki, Masashi Yamamoto, Hisayuki Okada, Kozo Hoshino, Kazushige Kadota, Yoshihiro Morino, Keiichi Igarashi, Kengo Tanabe, Ken Kozuma, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2015)
Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): Treatment results and toxicity profile
Authors: D. Gholam, S. Giacchetti, C. Brezault Bonnet, M. Bouchahda, R. Sverdlin, R. Adam, C. Jasmin, F. Levi
Journal: Journal of Clinical Oncology (2004)

3551 Background: Combination of FLO or IFL showed superiority over FL in phase III studies in ACRC (Giacchetti, JCO, 2000 - Douillard, JCO, 2000). Chronotherapy showed an impact on tolerability and activity of oxaliplatin, fluorouracil, and irinotecan (Lévi, Lancet, 2001). Methods: 71 patients (pts) received 608 courses (c) of a 5-day chrono IFLO delivered with a multichannel pump (Melodie, Aguettant, F) q 3 weeks (starting dose: I:160, F:2800, L:1200, O:75 mg/m2/c). Thirty-seven pts were men and 34 women. Median age: 58 years (33–82); WHO performance status (PS) 0/I/II: 38/21/12 pts; number of organs involved 1/2/3: 22/36/13 pts; liver: 83% pts; lung: 28%; peritoneum: 28%; prior chemotherapy lines: 2/3/4+: 25%/45%/30% pts; prior FLO and IFL: all pts. Toxicity was assessed every 3 weeks. Response was evaluated every 3c with CT scan and abdominal ultrasound. Results: A median of 7 c (2–20) was administered. Main grade 3–4 toxicities were diarrhea (44% pts, 8% c), neutropenia (31% pts, 6%c), nausea or vomiting (28% pts, 4% c), thrombocytopenia (6% pts, 0,8% c), mucositis (3% pts, 0,5% c). Grade 3 sensory neuropathy occurred in 15% pts only despite extensive prior oxaliplatin. PS remained ≤ 1 in 77% of the pts. 53 pts had stable disease. 3 pts, all with initial PS= 0, had a partial response >50%. Median time to progression is 6 months. At 15 months, overall survival rate is 51% [95% CI, 39 to 63]. Conclusions: After failure of both FLO and IFL, Chrono IFLO offered survival benefit, with good tolerability and quality of life in heavily pre-treated ACRC patients. Chrono IFLO deserves randomized evaluation as a third-line treatment of ACRC. No significant financial relationships to disclose.
Treating Hodgkin Lymphoma without Dacarbazine: A Lesson Learned from Thailand
Authors: Tawatchai Suwanban, Chajchawan Nakhakes, Arnuparp Lekhakula, Jakrawadee Julamanee, Lalita Norasetthada, Weerasak Nawarawong, Kanchana Chansung, Chittima Sirijerachai, Archrob Khuhapinant, Noppadol Siritanaratanakul, Udomsak Bunworasate, Tanin Intragumtornchai, Tontanai Numbenjapon, Kannadit Prayongratana, Pimjai Nipharuck, Suporn Chuncharunee, Somchai Wongkhantee, Peerapon Wong, Nonglak Kanitsap, Rachanid Pornuipavee, Nisa Makruasi
Journal: Blood (2015)
Metabolite-Sensing G Protein–Coupled Receptors—Facilitators of Diet-Related Immune Regulation
Authors: Jian K. Tan, Craig McKenzie, Eliana Mariño, Laurence Macia, Charles R. Mackay
Journal: Annual Review of Immunology (2017)

Nutrition and the gut microbiome regulate many systems, including the immune, metabolic, and nervous systems. We propose that the host responds to deficiency (or sufficiency) of dietary and bacterial metabolites in a dynamic way, to optimize responses and survival. A family of G protein–coupled receptors (GPCRs) termed the metabolite-sensing GPCRs bind to various metabolites and transmit signals that are important for proper immune and metabolic functions. Members of this family include GPR43, GPR41, GPR109A, GPR120, GPR40, GPR84, GPR35, and GPR91. In addition, bile acid receptors such as GPR131 (TGR5) and proton-sensing receptors such as GPR65 show similar features. A consistent feature of this family of GPCRs is that they provide anti-inflammatory signals; many also regulate metabolism and gut homeostasis. These receptors represent one of the main mechanisms whereby the gut microbiome affects vertebrate physiology, and they also provide a link between the immune and metabolic systems. Insufficient signaling through one or more of these metabolite-sensing GPCRs likely contributes to human diseases such as asthma, food allergies, type 1 and type 2 diabetes, hepatic steatosis, cardiovascular disease, and inflammatory bowel diseases.
Microrna-143 Blocks ERK5 Signaling During Granulocytic Differentiation of Hematopoietic Stem Cells and Is Downregulated in AML
Authors: Jens-Uwe Hartmann, Daniela Braeuer-Hartmann, Cindy Schödel, Dennis Gerloff, Christiane Katzerke, Carsten Müller-Tidow, Daniel G. Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2012)
Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.
Authors: Charles G. Mullighan, J. Racquel Collins-Underwood, Letha A Phillips, Michael G. Loudin, Wei Liu, Jinghui Zhang, Jing Ma, Elaine Coustan-Smith, Richard C. Harvey, Cheryl L. Willman, Jinjun Cheng, Fady M. Mikhail, Julia Meyer, Richard T Williams, Andrew J. Carroll, Nyla A. Heerema, Giuseppe Basso, Andrea Pession, Ching-Hon Pui, Susana C. Raimondi, Stephen P Hunger, James R. Downing, William L. Carroll, Karen R. Rabin
Journal: Blood (2009)
A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
Authors: J. J. Hwang, S. Park, A. Amin, R. R. Martin, T. Sullivan, T. Burns, S. Agrawal, M. J. Waxdal, S. Malik, J. L. Marshall
Journal: Journal of Clinical Oncology (2004)

3111 Background: HYB2055 (IMOxine) is a 2nd generation immunomodulatory oligonucleotide (IMO TM) that is thought to activate the innate immune system through the TLR9 receptor. In human cell-based assays, IMOxine has induced Th-1 responses. In nude mouse xenografts with colon, breast, lung cancer, and glioma cell lines, IMOxine showed potent antitumor activity. Methods: IMOxine is a weekly (wk) subcutaneous injection, with 1 cycle being 4 injections. This study is to evaluate 5 Dose Levels (DL: A:0.04; B:0.16; C:0.32; D:0.48; E: 0.64 mg/kg/wk). Pt eligibility criteria are standard for phase I trials. Typical phase I escalation schema is used, with dose escalation if 0/3 or 0–1/6 pt have dose limiting toxicity (DLT). DLT are any grade (gr) 4 toxicity, or any gr 3 non-hematologic toxicity preventing re-treatment for 2 wk. The maximum tolerated dose is the highest DL with 0–1/6 pt with DLT. Plasma is collected for measurement of selected cytokines and for pharmacokinetics of IMOxine. T and B lymphocyte subsets, monocyte/macrophages, dendritic cells, and NK cells are elucidated by flow cytometry. NK cell activity is assayed. Results: To 12/15/03, 16 pt (12 male) age 41–82 have been enrolled on 4 DL (A: 3; B:4; C:4; D:5 pts), and have received a total of 136 injections. Group E is open for enrollment. No DLT have occurred. Of 10 pt evaluable after 8 wk of therapy, 6 had stable disease (SD), and 2/4 had SD at 16 wk. One pt with metastatic Hurthle cell carcinoma has SD after 6 months, and continues on therapy. Mild to moderate erythema (typically maximal at 48hr) and induration were noted in 13/16 pts. Mainly gr 1 toxicities have occurred: Fatigue (11); chills or fever (9); myalgia (5); headache (4); abdominal discomfort (3); diarrhea, constipation, anorexia, nausea (2); hypotension (1). Immunopharmacology results at 24hr post injection show transient decreases in circulating lymphocytes and trends of increases in CD69+ and/or CD86+ activated lymphocytes. Circulating B cell percentages increased more gradually. Conclusions: IMOxine has been administered safely through 136 total doses, including a maximum of 25 weekly doses to date in 1 pt. Immunological activity has been demonstrated over the range of doses studied. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Hybridon, Inc. Boerhinger-Ingelheim; Hybridon, Inc. Hybridon, Inc. Roche Hybridon, Inc.
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Authors: R. Ramlau, V. Westeel, Z. Papai, A. Riviere, A. Madroszyk, P. Koralewski, G. Lacoste, B. Acres, J. M. Limacher, E. Quoix
Journal: Journal of Clinical Oncology (2008)

8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1. Methods: This is a randomized, open label and multicenter study. Eligibility criteria were: histologically documented and untreated stage IIIB “wet”/IV NSCLC, MUC1 positive tumor, ECOG PS 0–1. Patients were randomized to receive: Cisplatin 75mg/m2 on d1 and Gemcitabine 1250mg/m2 on d1 and d8 every 3 weeks for up to 6 cycles with or without TG4010 which was continued upon progression. Tumors were evaluated every 6 weeks (WHO criteria). Primary endpoint was progression-free survival (PFS) at 6 months; secondary endpoints included overall survival, response rate, safety, quality of life and immune response. Results: 148 patients were randomized: 107 men / 41 women, mean age: 59 years, 134 patients with stage IV disease / 14 with stage IIIB, 105 patients with PS 1 / 43 with PS 0. Demographics did not differ between both arms. The preliminary efficacy results provided by local evaluation on 140 evaluable patients are the following: in the experimental arm, 30/70 patients (43%; 95% CI 0.31–0.55) presented a confirmed partial response (PR) versus 18/70 (26%; 95% CI 0.16–0.36) in the control arm. Most adverse events (AEs) were considered related to chemotherapy or to underlying disease. Hematologic toxicity was equivalent in both arms. Most frequent AEs related to TG4010 were injection site reactions and asthenia, classical vaccine associated reactions. Preliminary immune response analysis indicates that both MUC1-specific and non-specific cellular immune responses are associated with the activity of TG4010. As median follow-up is 9 months, PFS, immune response and overall survival data are not yet mature but will be presented at the meeting. Conclusions: Based on preliminary data, the combination of TG4010 with first-line chemotherapy in NSCLC shows promising results with an increased response rate and a good safety profile. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Transgene SA Transgene SA Transgene
Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator’s choice therapy
Authors: G. Hess, J. E. Romaguera, G. Verhoef, R. Herbrecht, M. Crump, A. Strahs, J. Clancy, B. Hewes, B. Coiffier
Journal: Journal of Clinical Oncology (2008)

8513 Background: Temsirolimus (TEMSR) is a specific inhibitor of mTOR, a kinase that regulates translation of key cell cycle proteins such as cyclin D1. Mantle cell lymphoma (MCL) is characterized by an 11;14 translocation that results in overexpression of cyclin D1 mRNA. In this phase 3, randomized, open-label study, we compared the antitumor activity of TEMSR with an investigator’s choice of therapy (IC) in patients (pts) with relapsed and/or refractory MCL. Methods: To test the hypothesis that TEMSR would increase progression-free survival (PFS) compared with IC (assuming medians of 6.2 and 3.0 mo, respectively), accrual of 177 pts to achieve 105 PFS events was planned. Power was 80% and α=0.025 comparing TEMSR with IC. Pts must have received 2–7 prior lines of therapy and received an alkylating agent, an anthracycline, and rituximab. Pts were randomly assigned (1:1:1) to 1 of 2 schedules of IV TEMSR, 175 mg 3x weekly followed by either 75 mg (175/75, arm 1) or 25 mg (175/25, arm 2) weekly, or to IC (arm 3) with the single agents gemcitabine (42%); fludarabine (26%); chlorambucil, cladribine, etoposide (6% ea); cyclophosphamide, thalidomide, vinblastine (4% ea); or alemtuzumab, lenalinomide (2% ea). The primary endpoint was PFS based on central independent review of radiologic and clinical data. Results: We report final results for 162 pts (54 pts/arm, median age 67 y, 81% male, 50% >3 prior regimens, 32% prior stem cell transplant) after 105 PFS events. Treatment with TEMSR 175/75 mg resulted in significant improvement in PFS and objective response rate and a trend toward longer overall survival compared with IC (Table). The most frequently occurring adverse events ≥gr 3 were thrombocytopenia (arm 1: arm 2: arm 3, 59%: 52%: 36% pts), anemia (20%: 11%: 17%), neutropenia (15%: 22%: 26%), and asthenia (13%: 19%: 8%). Conclusions: With an acceptable safety profile, TEMSR 175/75 mg significantly increased PFS and objective response rate of pts with relapsed, refractory MCL compared with IC. Parameter TEMSR, 175/75 mg Arm 1 TEMSR, 175/25 mg Arm 2 IC, Arm 3 Progression-free survival, independent assessment Median (97.5% CI), mo 4.8 (3.1, 8.1) 3.4 (1.9, 5.5) 1.9 (1.6, 2.5) Increase in median * 153% 79% Hazard ratio (97.5% CI) * 0.44 (0.25, 0.78) 0.65 (0.39, 1.10) p-value * 0.0009 0.0618 Overall survival Median (95% CI), mo 10.9 (8.1, 14.1) 8.5 (5.8, 14.0) 5.8 (4.8, 12.4) Increase in median * 88% 47% Hazard ratio (95% CI) * 0.62 (0.37, 1.05) 0.80 (0.48, 1.33) p value * 0.0714 0.3876 Obj response rate (95% CI) 22% (11, 33) 6% (0, 12) 2% (0, 5) p-value * 0.0019 0.6179 * Arm 1 or arm 2 : arm 3 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Wyeth Research Wyeth Wyeth Pharmaceuticals Millennium, Wyeth
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
Authors: R.L. Ferris, J.L. Geiger, S. Trivedi, N.C. Schmitt, D.E. Heron, J.T. Johnson, S. Kim, U. Duvvuri, D.A. Clump, J.E. Bauman, J.P. Ohr, W.E. Gooding, A. Argiris
Journal: Annals of Oncology (2016)
Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).
Authors: A. Marwaha, N. W. Choong, S. Firat, C. J. Schultz, D. Wang, S. J. Wong
Journal: Journal of Clinical Oncology (2010)

5518 Background: Reirradiation (ReRT) with concurrent chemotherapy is a radical but potentially curative treatment modality for locally recurrent, non-metastatic SCCHN. ReRT studies commonly use split-course hyperfractionated radiation (RT). We report the experience of the Medical College of Wisconsin using continuous-course ReRT with concurrent weekly chemotherapy. Methods: Pts with unresectable locally recurrent, non-metastatic SCCHN or new primary SCCHN in a previously irradiated area were included. Pts received full-dose continuous course RT using 3-D CRT/IMRT and concurrent weekly paclitaxel (30-50mg/m2) and carboplatin (AUC2). Results: 38 pts were treated between 2001 and 2009. Pt demographics were: male 30 (79%), female 8 (21%), median age 62.5 yrs (42-81 yrs), site of primary tumor: oral 11 (29%), larynx 12 (32%), pharynx 14 (37%), and unknown primary site 1 (3%). Median duration between initial RT and ReRT was 4.6 yrs (0.33 – 18.8 yrs). Median follow up was 57 mos (4 - 229 mos). Median prior RT dose was 67.4 Gy (50- 78.2 Gy). Median ReRT dose was 60 Gy (40-70 Gy). Acute toxicity included grade 1/2 mucositis (10 pts; 26%), grade 3 mucositis (5 pts; 13%), grade 2 neutropenia (3 pts; 8%), grade 3 neutropenia (5 pts, 13%), and grade 1/2 thrombocytopenia (3 pts, 8%). Chemotherapy interruption (9 pts; 24%) was more prevalent than RT treatment break (2 pts; 5%). Only one incident of tracheoesophageal fistula was observed. Tumor response was: complete response 19 (50%), partial response 3 (8%), stable disease 8 (21%) and disease progression 8 (21%). Median overall survival was 23 mos. Eight pts lived greater than 2 yrs, all of whom had no evidence of disease at the time of last follow-up or death from unrelated cause. Conclusions: Continuous course ReRT with concurrent weekly carboplatin-paclitaxel has an acceptable toxicity profile and offers a potentially curative option in an otherwise incurable disease stage. No significant financial relationships to disclose.
Evaluation of Rural vs Urban Trauma Patients Served by 9-1-1 Emergency Medical Services
Authors: Craig D. Newgard, Rongwei Fu, Eileen Bulger, Jerris R. Hedges, N. Clay Mann, Dagan A. Wright, David P. Lehrfeld, Carol Shields, Gregory Hoskins, Craig Warden, Lynn Wittwer, Jennifer N. B. Cook, Michael Verkest, William Conway, Stephanie Somerville, Matthew Hansen
Journal: JAMA Surgery (2016)

Despite a large rural US population, there are potential differences between rural and urban regions in the processes and outcomes following trauma.To describe and evaluate rural vs urban processes of care, injury severity, and mortality among injured patients served by 9-1-1 emergency medical services (EMS).This was a preplanned secondary analysis of a prospective cohort enrolled from January 1 through December 31, 2011, and followed up through hospitalization. The study included 44 EMS agencies transporting to 28 hospitals in 2 rural and 5 urban counties in Oregon and Washington. A population-based, consecutive sample of 67 047 injured children and adults served by EMS (1971 rural and 65 076 urban) was enrolled. Among the 53 487 patients transported by EMS, a stratified probability sample of 17 633 patients (1438 rural and 16 195 urban) was created to track hospital outcomes (78.9% with in-hospital follow-up). Data analysis was performed from June 12, 2015, to May 20, 2016.Rural was defined at the county level by 60 minutes or more driving proximity to the nearest level I or II trauma center and/or rural designation in the Centers for Medicare & Medicaid Services ambulance fee schedule by zip code.Mortality (out-of-hospital and in-hospital), need for early critical resources, and transfer rates.Of the 53 487 injured patients transported by EMS (17 633 patients in the probability sample), 27 535 were women (51.5%); mean (SD) age was 51.6 (26.1) years. Rural vs urban sensitivity of field triage for identifying patients requiring early critical resources was 65.2% vs 80.5%, and only 29.4% of rural patients needing critical resources were initially transported to major trauma centers vs 88.7% of urban patients. After accounting for transfers, 39.8% of rural patients requiring critical resources were cared for in major trauma centers vs 88.7% of urban patients. Overall mortality did not differ between rural and urban regions (1.44% vs 0.89%; P = .09); however, 89.6% of rural deaths occurred within 24 hours compared with 64% of urban deaths. Rural regions had higher transfer rates (3.2% vs 2.7%) and longer transfer distances (median, 97.4 km; interquartile range [IQR], 51.7-394.5 km; range, 47.8-398.6 km vs 22.5 km; IQR, 11.6-24.6 km; range, 3.5-97.4 km).Most high-risk trauma patients injured in rural areas were cared for outside of major trauma centers and most rural trauma deaths occurred early, although overall mortality did not differ between regions. There are opportunities for improved timeliness and access to major trauma care among patients injured in rural regions.
Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Authors: Alicia Hulbert, Ignacio Jusue-Torres, Alejandro Stark, Chen Chen, Kristen Rodgers, Beverly Lee, Candace Griffin, Andrew Yang, Peng Huang, John Wrangle, Steven A. Belinsky, Tza-Huei Wang, Stephen C. Yang, Stephen B. Baylin, Malcolm V. Brock, James G. Herman
Journal: Clinical Cancer Research (2016)

Purpose: CT screening can reduce death from lung cancer. We sought to improve the diagnostic accuracy of lung cancer screening using ultrasensitive methods and a lung cancer-specific gene panel to detect DNA methylation in sputum and plasma.Experimental Design: This is a case-control study of subjects with suspicious nodules on CT imaging. Plasma and sputum were obtained preoperatively. Cases (n = 150) had pathologic confirmation of node-negative (stages I and IIA) non-small cell lung cancer. Controls (n = 60) had non-cancer diagnoses. We detected promoter methylation using quantitative methylation-specific real-time PCR and methylation-on-beads for cancer-specific genes (SOX17, TAC1, HOXA7, CDO1, HOXA9, and ZFP42).Results: DNA methylation was detected in plasma and sputum more frequently in people with cancer compared with controls (P < 0.001) for five of six genes. The sensitivity and specificity for lung cancer diagnosis using the best individual genes was 63% to 86% and 75% to 92% in sputum, respectively, and 65% to 76% and 74% to 84% in plasma, respectively. A three-gene combination of the best individual genes has sensitivity and specificity of 98% and 71% using sputum and 93% and 62% using plasma. Area under the receiver operating curve for this panel was 0.89 [95% confidence interval (CI), 0.80-0.98] in sputum and 0.77 (95% CI, 0.68-0.86) in plasma. Independent blinded random forest prediction models combining gene methylation with clinical information correctly predicted lung cancer in 91% of subjects using sputum detection and 85% of subjects using plasma detection.Conclusions: High diagnostic accuracy for early-stage lung cancer can be obtained using methylated promoter detection in sputum or plasma. Clin Cancer Res; 23(8); 1998-2005. ©2016 AACR.
GW27-e0181 Secreted frizzled related protein 1 protects H9C2 cells from hypoxia/re-oxygenation injury by blocking the Wnt signaling pathway
Authors: Jing Tao, Yining Yang, Xiaomei Li, Fen Liu, Bang-Dang Chen, Chunhui He, Huaying Li, Xiaocui Chen, Yitong Ma
Journal: Journal of the American College of Cardiology (2016)